European Commission approves Roche’s Gavreto to treat adults with RET fusion-positive advanced… EP News Bureau Nov 22, 2021 Gavreto is the first and only precision medicine approved in the EU for the first-line treatment of people with RET…
Genentech gets US FDA nod for Gavreto to treat RET-mutant, RET fusion-positive thyroid cancers EP News Bureau Dec 2, 2020 Gavreto is a once-daily, oral precision therapy designed to selectively target RET alterations, including fusions and mutations
Roche’s Genentech gets US FDA approval for Gavreto (pralsetinib) EP News Bureau Sep 5, 2020 The drug is used to treat metastatic RET fusion-positive non-small cell lung cancer
